... in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium ... 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and…
News
- Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with ...
- Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with ...
05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and ... a first-in-class glutaminase inhibitor, will be presented at the 2017 San Antonio Breast Cancer Symposium, December 5-9, 2017 in San Antonio, Texas.
- Galectin drops 40% on negative NASH result
It's rarely ever a positive sign when a biotech has to resort to slicing and dicing data in order to find a positive result. ... for the presence of esophageal varices," said Stephen Harrison, one of lead investigators of the NASH-CX trial and medical director of Pinnacle Clinical Research in…
- SA biotech lining up talent, science and cash in march to market
The San Antonio-based biotech is expanding its leadership team. It's also preparing to launch new clinical trials in support of its lead CyPath Lung ...
- Axios Pro Rata
NanoCellect Biomedical, a San Diego-based developer of microfluidic cell sorting technologies for cell-based assays, has raised $10 million in Series B ... EagleTree Capital has led the acquisition of a majority stake in WaterFleet, a San Antonio, Texas-based provider of mobile water and…